Compare
XBiotech Inc. vs Whitehawk Therapeutics, Inc. vs Ovid Therapeutics Inc. vs CytomX Therapeutics, Inc.
| Latest fiscal year | XBiotech Inc. XBIT | Whitehawk Therapeutics, Inc. WHWK | Ovid Therapeutics Inc. OVID | CytomX Therapeutics, Inc. CTMX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $7.14M | $7.25M | $76.20M |
| Revenue growth (YoY) | n/a | -72.5% | n/m | -44.8% |
| Gross margin | n/a | 89.4% (computed) | n/a | n/a |
| Operating margin | n/a | n/m | -585.2% | -29.3% |
| Net margin | n/a | -288.3% | -240.1% | -22.8% |
| Net income | -$45.54M | -$20.60M | -$17.41M | -$17.37M |
| EPS (Diluted) | -$1.49 | -$0.33 | n/a | n/a |
| Operating cash flow | -$39.92M | -$97.43M | -$38.33M | -$75.59M |
| Free cash flow | -$40.21M | -$97.98M | -$38.33M | -$75.81M |
| Cash & equivalents | $125.55M | $37.57M | $13.15M | $12.67M |
| Total assets | $150.08M | $150.83M | $150.93M | $151.57M |
| Total liabilities | $9.73M | $14.52M | $20.27M | $52.56M |
| Shareholders' equity | $140.35M | $136.31M | $130.66M | $99.01M |
| Return on year-end equity | -32.4% | -15.1% | -13.3% | -17.5% |
| Shares outstanding | 30.49M | 47.15M | 130.18M | 170.19M |
Revenue, most recent five fiscal years
| Fiscal year | XBiotech Inc. | Whitehawk Therapeutics, Inc. | Ovid Therapeutics Inc. | CytomX Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-12-31 | $7.14M Ended 2025-12-31 | $7.25M Ended 2025-12-31 | $76.20M Ended 2025-12-31 |
| 1 year earlier | $4.01M Ended 2022-12-31 | $25.98M Ended 2024-12-31 | $566.0K Ended 2024-12-31 | $138.10M Ended 2024-12-31 |
| 2 years earlier | $18.39M Ended 2021-12-31 | $24.35M Ended 2023-12-31 | $392.0K Ended 2023-12-31 | $101.21M Ended 2023-12-31 |
| 3 years earlier | $44.00M Ended 2020-12-31 | $15.22M Ended 2022-12-31 | $1.50M Ended 2022-12-31 | $53.16M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2019-12-31 | $14.00M Ended 2021-12-31 | $208.38M Ended 2021-12-31 | $37.31M Ended 2021-12-31 |